Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916).
Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. Muscal JA, et al. Among authors: espinoza delgado i. Pediatr Blood Cancer. 2013 Mar;60(3):390-5. doi: 10.1002/pbc.24271. Epub 2012 Aug 9. Pediatr Blood Cancer. 2013. PMID: 22887890 Free PMC article. Clinical Trial.
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.
Schelman WR, Traynor AM, Holen KD, Kolesar JM, Attia S, Hoang T, Eickhoff J, Jiang Z, Alberti D, Marnocha R, Reid JM, Ames MM, McGovern RM, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH. Schelman WR, et al. Among authors: espinoza delgado i. Invest New Drugs. 2013 Dec;31(6):1539-46. doi: 10.1007/s10637-013-0029-6. Epub 2013 Oct 10. Invest New Drugs. 2013. PMID: 24114121 Free PMC article. Clinical Trial.
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.
Deming DA, Ninan J, Bailey HH, Kolesar JM, Eickhoff J, Reid JM, Ames MM, McGovern RM, Alberti D, Marnocha R, Espinoza-Delgado I, Wright J, Wilding G, Schelman WR. Deming DA, et al. Among authors: espinoza delgado i. Invest New Drugs. 2014 Apr;32(2):323-9. doi: 10.1007/s10637-013-0035-8. Epub 2013 Oct 10. Invest New Drugs. 2014. PMID: 24114123 Free PMC article. Clinical Trial.
Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.
Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. Lee EQ, et al. Among authors: espinoza delgado i. Clin Cancer Res. 2012 Nov 1;18(21):6032-9. doi: 10.1158/1078-0432.CCR-12-1841. Epub 2012 Aug 24. Clin Cancer Res. 2012. PMID: 22923449 Free PMC article. Clinical Trial.
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. Kadia TM, et al. Br J Haematol. 2010 Jul;150(1):72-82. doi: 10.1111/j.1365-2141.2010.08211.x. Epub 2010 Apr 29. Br J Haematol. 2010. PMID: 20456355 Free PMC article. Clinical Trial.
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.
Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. Fakih MG, et al. Clin Cancer Res. 2010 Jul 15;16(14):3786-94. doi: 10.1158/1078-0432.CCR-10-0547. Epub 2010 May 12. Clin Cancer Res. 2010. PMID: 20463088 Free PMC article. Clinical Trial.
A phase 2 study of vorinostat in acute myeloid leukemia.
Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD; Mayo P2C Phase II Consortium. Schaefer EW, et al. Haematologica. 2009 Oct;94(10):1375-82. doi: 10.3324/haematol.2009.009217. Haematologica. 2009. PMID: 19794082 Free PMC article. Clinical Trial.
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. Fakih MG, et al. Clin Cancer Res. 2009 May 1;15(9):3189-95. doi: 10.1158/1078-0432.CCR-08-2999. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383814 Free PMC article. Clinical Trial.
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.
Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Kolesar JM, et al. Among authors: espinoza delgado i. Cancer Chemother Pharmacol. 2013 Sep;72(3):661-7. doi: 10.1007/s00280-013-2242-6. Epub 2013 Aug 1. Cancer Chemother Pharmacol. 2013. PMID: 23903894 Free PMC article. Clinical Trial.
58 results